Wealth Enhancement Advisory Services LLC Acquires Shares of 34,883 Smith & Nephew plc (NYSE:SNN)

Wealth Enhancement Advisory Services LLC bought a new position in Smith & Nephew plc (NYSE:SNN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 34,883 shares of the medical equipment provider's stock, valued at approximately $857,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SNN. Vident Advisory LLC lifted its position in Smith & Nephew by 158.8% during the fourth quarter. Vident Advisory LLC now owns 21,564 shares of the medical equipment provider's stock valued at $530,000 after purchasing an additional 13,232 shares during the period. Wexford Capital LP bought a new position in Smith & Nephew during the fourth quarter valued at approximately $541,000. Point72 Asset Management L.P. bought a new position in Smith & Nephew during the fourth quarter valued at approximately $6,132,000. Quantinno Capital Management LP lifted its position in Smith & Nephew by 83.8% during the fourth quarter. Quantinno Capital Management LP now owns 97,818 shares of the medical equipment provider's stock valued at $2,404,000 after purchasing an additional 44,592 shares during the period. Finally, J. Goldman & Co LP bought a new position in Smith & Nephew during the fourth quarter valued at approximately $47,700,000. Institutional investors own 25.64% of the company's stock.

Wall Street Analyst Weigh In

SNN has been the subject of a number of research reports. Wall Street Zen raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. Canaccord Genuity Group increased their price objective on shares of Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. UBS Group cut shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Hsbc Global Res cut shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, HSBC cut shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Six research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew Price Performance

SNN traded down $0.79 during trading on Friday, hitting $29.33. 838,174 shares of the company traded hands, compared to its average volume of 799,076. The company has a market cap of $12.84 billion, a PE ratio of 13.58, a P/E/G ratio of 1.26 and a beta of 0.68. The stock's 50-day simple moving average is $27.86 and its two-hundred day simple moving average is $26.81. Smith & Nephew plc has a 1 year low of $23.69 and a 1 year high of $31.72. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.